CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial

HOUSTON, Oct. 29, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that its European manufacturer, BSP Pharmaceuticals S.p.A. (“BSP”), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable. With the completion of manufacturing at BSP and at its U.S. manufacturer, Pharmaceutics International, Inc. (“Pii”), the Company remains poised to file an Investigational New Drug Application (“IND”) and initiate its Phase 2 U.S. clinical trial for Berubicin on its anticipated timeline.

The release as fetched from its publisher. cnspharma.com ↗